Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Outlook Therapeutics (Nasdaq: OTLK) announced that CEO Bob Jahr will participate in a live fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 10:00 AM ET.
Management is also available for one-on-one in-person meetings with qualified, registered investors at the conference. A live webcast will be available on the company Investors > Events page and the replay will be archived for 90 days after the event.
Outlook Therapeutics (Nasdaq: OTLK) ha annunciato che il CEO Bob Jahr parteciperà a una live fireside chat alla Piper Sandler 37th Annual Healthcare Conference il martedì 2 dicembre 2025 alle 10:00 ET.
Anche la direzione è disponibile per incontri individuali di persona con investitori qualificati e registrati durante la conferenza. Una trasmissione in diretta sarà disponibile sulla pagina Investors > Events dell'azienda e la replica sarà archiviata per 90 giorni dopo l'evento.
Outlook Therapeutics (Nasdaq: OTLK) anunció que el CEO Bob Jahr participará en una charla informal en vivo en la Piper Sandler 37th Annual Healthcare Conference el martes 2 de diciembre de 2025 a las 10:00 a. m. ET.
La dirección también está disponible para reuniones en persona, una a una, con inversionistas calificados y registrados durante la conferencia. Una transmisión en vivo estará disponible en la página de la empresa Investors > Events y la repetición estará archivada por 90 días después del evento.
Outlook Therapeutics (Nasdaq: OTLK)는 CEO Bob Jahr가 Piper Sandler 37th Annual Healthcare Conference의 라이브 파이어사이드 채팅에 2025년 12월 2일 화요일 10:00 AM ET에 참여한다고 발표했습니다.
경영진은 컨퍼런스 기간 동안 자격을 갖춘 등록 투자자들과의 일대일 대면 미팅도 가능합니다. 생방송은 회사의 Investors > Events 페이지에서 시청 가능하며 이벤트 후 재방송은 90일 동안 보관됩니다.
Outlook Therapeutics (Nasdaq: OTLK) a annoncé que le PDG Bob Jahr participera à une conversation informelle en direct lors de la Piper Sandler 37th Annual Healthcare Conference le mardi 2 décembre 2025 à 10:00 AM ET.
La direction est également disponible pour des réunions en tête-à-tête avec des investisseurs qualifiés et inscrits pendant la conférence. Une diffusion en direct sera disponible sur la page Investors > Events de l'entreprise et la rediffusion sera archivée pendant 90 jours après l'événement.
Outlook Therapeutics (Nasdaq: OTLK) gab bekannt, dass der CEO Bob Jahr an einem Live-Fireside-Chat bei der Piper Sandler 37th Annual Healthcare Conference am Dienstag, dem 2. Dezember 2025 um 10:00 Uhr ET teilnehmen wird.
Das Management steht außerdem für persönliche One-on-One-Gespräche mit qualifizierten, registrierten Investoren während der Konferenz zur Verfügung. Ein Live-Webcast ist auf der Unternehmensseite Investors > Events verfügbar, und die Aufzeichnung wird 90 Tage nach der Veranstaltung archiviert.
Outlook Therapeutics (Nasdaq: OTLK) أعلنت أن الرئيس التنفيذي Bob Jahr سيشارك في دردشة حوارية حية على هامش مؤتمر Piper Sandler 37th Annual Healthcare Conference في الثلاثاء 2 ديسمبر 2025 الساعة 10:00 صباحاً بتوقيت شرق الولايات المتحدة.
كما تتاح للإدارة عقد لقاءات شخصية وجهًا لوجه مع المستثمرين المؤهلين والمسجلين خلال المؤتمر. ستتوفر بث مباشر على صفحة الشركة Investors > Events وسيتم أرشفة إعادة البث لمدة 90 يوماً بعد الحدث.
- None.
- None.
Live webcast fireside chat on Tuesday, December 2nd at 10:00 AM ET
ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that Bob Jahr, Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 10:00 AM ET.
In addition to the fireside chat, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference.
A live webcast of the fireside chat will be accessible on the Events page in the Investors section of the Company’s website (outlooktherapeutics.com). The webcast replay will be archived for 90 days following the event.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.
In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
FAQ
When will Outlook Therapeutics (OTLK) present at the Piper Sandler 2025 conference?
How can investors watch the Outlook Therapeutics (OTLK) fireside chat webcast?
Will Outlook Therapeutics (OTLK) offer meetings with management at the conference?
How long will the Outlook Therapeutics (OTLK) webcast replay be available?
What topics will Outlook Therapeutics (OTLK) cover in the fireside chat on December 2, 2025?
